RMAH.RO Farmaceutica R
- Market cap
- RON 76.6M
- P/E
- 20.3x
- P/B
- 1.03x
- ROE
- 4.7%
- Dividend yield
- 4.37%
- Fundamental score
- 2.7/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is RMAH.RO undervalued?
Graham numberRMAH.RO trades 3.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Farmaceutica R fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (4.7%), below 10%.
ROA 0/1
Return on assets (1.0%) is below the industry median (2.4%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (17.3%) is above the 5-year average (-24.8% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (17.3%) is above the industry median (1.4%).
Revenue Growth 2/2
Revenue grew 12.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 193.3x against interest expense, well covered.
PE vs Market 0/1
PE (20.5x) is above the market median (18.3x).
PE vs Industry 0/1
PE (20.5x) is above the industry median (18.3x).
PBV 1/1
Price to book (1.0x) is below the industry median (1.1x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 21.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (4.4%) is in the top 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 41.7%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Farmaceutica R stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Farmaceutica R
Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. It is also involved in the wholesale distribution of medicines to pharmacies, and public and private hospitals and clinics. In addition, the company provides packaging materials; and logistics and warehousing, promotion and marketing of drugs, and pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania.
Full company profileFarmaceutica R financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Farmaceutica R annual financial statements (RON; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 441M | 477M | 536M | 593M | 744M | 760M | 739M |
| Gross Profit | 46.7M | 38.0M | 44.4M | 45.8M | 58.0M | 60.5M | 58.4M |
| Operating Income | 4.45M | 8.79M | 7.14M | 7.53M | 13.5M | 14.9M | 6.88M |
| EBITDA | - | - | 11.2M | 14.1M | 16.8M | 18.7M | 11.9M |
| Net Income | 37.8M | 7.23M | 5.81M | 7.20M | 6.96M | 8.04M | 3.48M |
| EPS | 0.36 | 0.08 | 0.06 | 0.08 | 0.07 | 0.09 | 0.04 |
| Balance Sheet | |||||||
| Total Assets | 244M | 251M | 286M | 316M | 375M | 383M | 345M |
| Total Liabilities | 165M | 183M | 218M | 245M | 301M | 304M | 272M |
| Shareholders' Equity | 79.8M | 68.2M | 68.4M | 70.9M | 73.9M | 79.6M | 73.5M |
| Cash & Short-term Investments | 34.4M | 24.2M | 18.1M | 34.5M | 47.7M | 57.9M | 38.5M |
| Cash Flow | |||||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -13.5M | 2.63M | -1.99M | 23.2M | 19.0M | 15.5M | -21.7M |
| Ratios | |||||||
| ROE | 47.3% | 10.6% | 8.5% | 10.2% | 9.4% | 10.1% | 4.7% |
| ROA | 15.5% | 2.9% | 2.0% | 2.3% | 1.9% | 2.1% | 1.0% |
| Net Profit Margin | 8.6% | 1.5% | 1.1% | 1.2% | 0.9% | 1.1% | 0.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Farmaceutica R dividends
- Dividend yield
- 4.37%
- Forward dividend
- 0.05 RON
- Payout ratio
- 41.7%
- Ex-dividend date
- Sep 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | RON 3.35M | 0.04 | 41.7% |
| 2024 | RON 6.29M | 0.07 | 90.3% |
| 2023 | RON 4.19M | 0.04 | 58.2% |
| 2022 | RON 4.47M | 0.05 | 76.9% |
| 2021 | RON 13.4M | 0.14 | 184.6% |
| 2020 | RON 1.99M | 0.02 | 5.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Farmaceutica R
- Insiders 80.56%
- Institutions 0.00%
- Public & others 19.45%
- Shares outstanding 93.7M
- Free float 16.8M
Farmaceutica R company profile
- Company name
- Farmaceutica R
- Ticker
- RMAH.RO
- ISIN
- RORMAHACNOR2
- Exchange
- Bucharest Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Distribution
- Employees
- 210
- Fiscal year end
- September
- Address
- Nicolae Balcescu Bld. no 2, Deva, Romania, 330040
- Phone
- 40 25 422 3260
- Website
- corporate.remedia.ro
About Farmaceutica R
Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. It is also involved in the wholesale distribution of medicines to pharmacies, and public and private hospitals and clinics. In addition, the company provides packaging materials; and logistics and warehousing, promotion and marketing of drugs, and pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania.
Farmaceutica R management
8- Mr. Valentin-Norbert TarusPresident of Board of Administrators & GM · born 1953
- Ms. Elena CodreanChief Financial Officer · born 1982
- Mr. Florin LupasAdministrative Manager · born 1977
- Ms. Diana NeaguMarketing Manager
- Ms. Cristina RaduHR Director · born 1986
- Mr. Cristian PloconExecutive Non-Independent Administrator · born 1977
- Mr. Florin CadiaDirector of Sustainability · born 1975
- Theodor Cojocaru-TothExecutive Non-Independent Administrator